813426-13-0 Usage
Uses
Used in Pharmaceutical Industry:
SPIRO is utilized as a pharmaceutical agent for its potential therapeutic applications. Its unique spiro structure and carboxylic acid group contribute to its biological activities, making it a candidate for the development of new drugs targeting various diseases and conditions.
Used in Chemical Research:
In the field of chemical research, SPIRO serves as a subject of study for understanding its properties, reactivity, and potential applications. Its unique structure allows researchers to explore new synthetic pathways and investigate its interactions with other molecules, paving the way for the discovery of novel compounds and materials.
Used in Drug Design and Development:
SPIRO is employed in drug design and development due to its potential as a lead compound. Its spiro skeleton and carboxylic acid group can be modified to create new derivatives with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability. This makes SPIRO a valuable starting point for the development of innovative therapeutic agents.
Used in Material Science:
In material science, SPIRO can be explored for its potential use in the creation of new materials with unique properties. Its spiro structure and functional groups may contribute to the development of advanced materials with applications in various industries, such as electronics, coatings, and adhesives.
Check Digit Verification of cas no
The CAS Registry Mumber 813426-13-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,1,3,4,2 and 6 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 813426-13:
(8*8)+(7*1)+(6*3)+(5*4)+(4*2)+(3*6)+(2*1)+(1*3)=140
140 % 10 = 0
So 813426-13-0 is a valid CAS Registry Number.
813426-13-0Relevant articles and documents
Novel solid forms of (4R)-1-[2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5- tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
-
Page/Page column 11, (2008/06/13)
The present invention relates to novel solid forms of (4R)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4H-1-benzazepine-4,1′-[2]cyclopentene]-3′-carboxylic acid (formula (I)) useful for treating and/or preventing condit
Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
-
Page 18, (2008/06/13)
Novel spirobenzoazepine compounds, novel processes for the preparation of nonpeptide substituted spirobenzoazepine derivatives, and novel processes for the preparation of intermediates in the preparation of such derivatives. Novel intermediates in the preparation of nonpeptide substituted spirobenzoazepine derivatives.
Substituted spirobenzazepines
-
Page 16, (2008/06/13)
The invention is directed to nonpeptide substituted benzazepines of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension, among others disclosed. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.
